News
NextCure
NXTC · NASDAQ
$5.44−$0.23 (−4.06%)TodayMarket closed ·
Prev close $5.67
Latest news
- Press releasePRNewswire
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB
- Press releasePRNewswire
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
- NewsVandana Singh
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)
- NewsAvi Kapoor
Dow Falls Over 100 Points Following Inflation Data; Crude Oil Gains
- Press releasePRNewswire
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
- Press releaseBusiness Wire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
- NewsAvi Kapoor
Nasdaq Surges Over 100 Points; Bank of America Earnings Top Views
- Press releaseGlobe Newswire
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
- Press releaseGlobe Newswire
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
- Press releaseGlobe Newswire
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
- Press releaseGlobe Newswire
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
- NewsAvi Kapoor
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
- NewsMohd Haider
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
- Press releaseGlobe Newswire
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
NextCure Announces Acceptance of IND Application for LNCB74
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.